The Measles Virus (Rubeola)

Tutor's Note & Terminology Trap

Always remember that Rubeola is Measles. Do not confuse it with Rubella (German Measles) or Roseola (caused by Human Herpesvirus 6 / HHV-6). Measles is an acute, highly contagious, generalized viral infection primarily affecting children, characterized by a distinct prodrome (runny nose, cough, red eyes) and a classic maculopapular rash.

I. Classification and Etiology

Understanding the exact taxonomy of the measles virus helps predict its behavior, structure, and vulnerability.

Family: Paramyxoviridae. (This family also includes Mumps, Respiratory Syncytial Virus (RSV), and Parainfluenza viruses).
Genus: Morbillivirus.
Species/Cause: Measles virus.

Host Range & Serotypes

Host: Humans are the only natural host and reservoir. There is absolutely no animal or environmental reservoir.
Serotype: Only one single serotype is known to exist globally.
Public Health Significance: Because there is only one serotype (it does not mutate its surface proteins rapidly like Influenza) and no animal reservoir, Measles is an excellent theoretical candidate for global eradication (just like Smallpox and Rinderpest)! Once a person is immunized, they are immune for life.

II. Morphology and Viral Structure

Measles is an enveloped, pleomorphic (often spherical) viral particle. Its structural components are highly testable on microbiology and pathology exams.

1. The Genome

It is a Single-stranded, linear, non-segmented, negative-sense RNA virus.
Molecular Expansion: Because it is "negative-sense," the raw viral RNA cannot be directly translated into proteins by the host cell's ribosomes. The virus is forced to carry its own specialized enzyme—RNA-dependent RNA polymerase (RdRp)—inside its virion to transcribe a positive-sense mRNA strand first!

2. The Capsid

Possesses Helical symmetry, enclosing the RNA genome securely to protect it from environmental nucleases.
Surrounded by a lipid envelope derived from the host cell membrane during viral budding.

Surface Spikes (Peplomers)

The viral envelope contains two highly critical glycoprotein spikes that act as keys to enter human cells:

Hemagglutinin (H protein): Mediates the initial attachment of the virus to the host cell. It specifically binds to the CD46 cellular receptor (found on all nucleated human cells), SLAM (CD150) (found on immune cells), and Nectin-4 (found on epithelial cells).
Crucial Note: Unlike many other paramyxoviruses (like Mumps or Parainfluenza), the measles H protein strictly lacks neuraminidase activity.
Fusion (F protein): Responsible for fusing the viral lipid envelope with the host cell membrane to allow the viral genome to slip inside.
Pathological Consequence: It is also responsible for cell-to-cell fusion, creating giant multinucleated cells (syncytia), and causes viral hemolysis.

🧠 Mnemonic: Paramyxovirus Features

Think "Paramyxo is PaRa-M-X-O"

Pleomorphic/Spherical
RNA (Single-stranded, Negative sense)
Morbillivirus (Measles)
X (No segmented genome - it is non-segmented)
One serotype

III. Epidemiology

Historical & Global Context

Measles is highly endemic throughout the world. Despite the incredible effectiveness of the live-attenuated vaccine, it still causes approximately 2 million deaths annually worldwide, largely in developing nations lacking robust vaccination infrastructure.

Pre-Vaccine Era: Epidemics tended to occur irregularly, appearing in the spring in large cities at 2-to-4-year intervals as new cohorts of susceptible children were born, lost maternal antibodies, and were exposed. The peak incidence was among children 5-10 years of age.
Natural Immunity: Individuals born before 1957 are generally considered to have survived natural infection and are presumed to possess lifelong natural immunity. Most women of childbearing age in the US and developed nations now rely on immunity via vaccination rather than natural disease.

Maternal & Infant Immunity

Transplacental Protection: Infants acquire immunity transplacentally because maternal IgG antibodies readily cross the placenta. This applies to mothers who have had natural measles or the measles immunization.
Waning Immunity: This maternal immunity is usually robust for the first 4-6 months of life but wanes at a variable rate. However, trace amounts of protection can persist up to 11 months. Why does this matter? Because these lingering maternal antibodies will immediately attack and destroy a live measles vaccine, rendering it useless! This interference is exactly why routine live MMR immunizations are delayed until 12-15 months of age in developed countries.
Clinical Note: Infants of mothers with vaccine-induced immunity actually lose passive antibody protection at a younger age than infants of mothers who survived the natural, wild-type measles infection.
Zero Protection: Infants born to completely susceptible mothers (no vaccine, no prior disease) have zero protection and can contract the disease simultaneously with the mother before or even after delivery.

Clinical Presentation Rate: Measles is almost never subclinical. If a non-immune individual is infected by the virus, they will almost certainly manifest symptomatic disease.

IV. Transmission Dynamics

Measles is widely considered one of the most highly contagious infectious diseases known to humanity. It has an estimated R0 (Basic Reproduction Number) of 12 to 18, meaning one infected person will, on average, infect 12 to 18 completely susceptible people.

Method of Spread: Spread predominantly via airborne respiratory droplets (droplet spray) produced by coughing, breathing, or sneezing. Fomite transmission (touching a contaminated surface and then touching mucous membranes) also occurs.
Airborne Survival: The virus stays active and highly contagious suspended in the air and on surfaces for up to 2 hours after the infected person has physically left the room!
Attack Rate: Approximately 90% of susceptible household contacts will acquire the disease.
Contagious Window: An infected person can actively spread the virus from 4 days BEFORE the rash appears to 4 days AFTER the rash appears.
Maximal Dissemination: The absolute highest viral shedding occurs by droplet spray during the prodromal period (the catarrhal stage, when the patient is coughing and sneezing profusely, well before the classic rash is even visible!). Transmission to contacts almost always occurs prior to the diagnosis of the index case.

Applied Clinical Scenario: Transmission Window

Scenario: A mother brings her 4-year-old unvaccinated child to the clinic on Tuesday with a distinct maculopapular rash that began that morning. She asks when her child was likely spreading the virus at his crowded daycare.

Answer & Rationale: Based on the strict contagious period of measles, the child was highly contagious starting 4 days before the rash appeared (meaning the previous Friday). The child will remain contagious until 4 days after the rash appeared (the upcoming Saturday). This extended window is exactly why measles outbreaks spread like wildfire—children are highly infectious during the prodrome when teachers and parents simply assume they have a regular, harmless cold!

V. Pathogenesis & Cellular Effects

Entry and Viral Spread

Step 1: Initial infection and viral replication occur deep in the respiratory tract epithelium and conjunctiva.
Step 2: The virus drains into regional lymph nodes, replicates further, and spills into the blood, causing a primary viremia (virus in the bloodstream).
Step 3: Massive dissemination to many organ systems occurs, including massive infection of the reticuloendothelial system (RES - spleen, liver, lymph nodes), followed by a massive secondary viremia that drives the virus into the skin, respiratory mucosa, and conjunctivae.

The Essential Lesions & Cellular Effects

The essential pathologic lesions of measles are found in the skin, conjunctivae, mucous membranes of the nasopharynx, bronchi, and the intestinal tract. A serous exudate and proliferation of mononuclear cells (macrophages/lymphocytes) occur around the local capillaries in these regions.

Warthin-Finkeldey Giant Cells (Pathological Hallmark)

Hyperplasia of lymphoid tissue occurs extensively (particularly notable in the appendix and lymph nodes). The measles virus—specifically via the action of its F-protein (Fusion protein)—causes infected cells to literally melt and fuse together with neighboring healthy cells.

This induces the formation of massive, multinucleated giant cells (syncytia) known pathologically as Warthin-Finkeldey reticuloendothelial giant cells. These massive cells can contain up to 100 nuclei, measure up to 100 µm in diameter, feature eosinophilic intranuclear and intracytoplasmic inclusions, and are an absolute hallmark of measles infection in lymphoid tissues.

Why does the virus do this? By fusing cells together, the virus can spread its genome from cell to cell without ever entering the extracellular space, effectively hiding from circulating neutralizing antibodies!

Pathogenesis of the Rash (The Exanthem)

Surprisingly, the characteristic red rash of measles is not directly caused by the virus killing skin cells. The rash is an immune-mediated response!

Mechanism: The rash is primarily caused by host cytotoxic CD8+ T cells actively hunting down and attacking the measles virus-infected vascular endothelial cells located in the skin's capillary beds.
Clinical Proof: In severely immunocompromised HIV patients who lack functional T-cells, they may contract a fatal case of measles pneumonia and encephalitis, yet never develop the classic rash because they lack the T-cells required to create the inflammatory skin response!

Other Mucosal Lesions

Koplik Spots: These are the classic oral lesions of measles. Pathologically, they consist of serous exudate, proliferation of endothelial cells, and focal necrosis, similar to the skin lesions but occurring in the mouth.
A general inflammatory reaction of the buccal and pharyngeal mucosa extends deep into the lymphoid tissue and the tracheobronchial mucous membrane, causing severe cough.

VI. Clinical Manifestations Overview

Measles follows a highly predictable, textbook clinical course. It is classically divided into three distinct clinical stages:

Stage 1

The Incubation Stage: The silent period of initial viral replication, lymph node spread, and primary viremia.

Stage 2

The Prodromal Stage: Characterized by an enanthem (mucous membrane rash, specifically Koplik's spots) and mild-to-severe systemic respiratory symptoms.

Stage 3

The Exanthem Stage: Characterized by a spreading maculopapular skin rash accompanied by a remarkably high fever peak.

VII. Stage 1: The Incubation Period

Duration: Lasts approximately 10 to 12 days from the moment of respiratory exposure to the onset of the first prodromal symptoms. It takes another 2-4 days for the rash to appear (making the rash predictably appear around Day 14 post-exposure). Rarely, the incubation may be as short as 6-10 days.
Physiological Temperature Shifts: Body temperature may increase slightly 9-10 days from the date of infection (as the massive secondary viremia begins), and then magically subside for 24 hours or so, lulling parents into a false sense of security before the severe prodrome strikes.
Transmission Window: The patient is shedding virus from the respiratory tract and may transmit it by the 9th-10th day after exposure (and occasionally as early as the 7th day). They are highly contagious before any doctor can clinically diagnose them.

VIII. Stage 2: The Prodromal Phase

The prodromal phase usually lasts 3 to 5 days and represents the peak of viral dissemination and respiratory mucosal inflammation.

🧠 Mnemonic: The Prodrome of Measles

Always remember the "3 C's and a K" for Measles diagnosis:

Cough (Usually a severe, dry, hacking cough due to tracheobronchial inflammation).
Coryza (Severe rhinitis / profoundly runny nose).
Conjunctivitis (Red, inflamed eyes accompanied by intense photophobia/light sensitivity).
Koplik's Spots.

Diagnostic Ocular Signs

The conjunctival inflammation and photophobia may strongly suggest measles even before Koplik's spots appear. A pathognomonic eye sign—a transverse line of conjunctival inflammation, sharply demarcated along the eyelid margin (often called the Stimson line)—may be of immense diagnostic assistance in the early prodromal stage. As the entire conjunctiva becomes completely red and involved later, this specific line disappears.

Progression of Severity

Occasionally, the prodromal phase may be exceedingly severe, ushered in by a sudden high fever, sometimes accompanied by febrile convulsions and even early viral pneumonia.
Usually, the coryza, fever, and cough become increasingly severe right up to the exact moment the rash covers the body.
The Fever Peak: The temperature rises abruptly as the rash begins to appear, often reaching a dangerously high 40°C (104°F) or higher!

IX. Koplik's Spots (The Enanthem)

Koplik's spots are the absolute pathognomonic sign of measles. If a physician identifies them in a febrile child, the diagnosis of measles is essentially 100% confirmed; no other known disease causes them.

Appearance: They are an enanthem (mucosal rash). Classically, they appear as tiny grayish-white or bluish-white dots, often vividly described as resembling "grains of salt on a wet red background". They are extremely small (1-3mm), surrounded by a slight, reddish inflammatory areola. Occasionally, they can be hemorrhagic.
Location: Tend to occur on the buccal mucosa (inside of the cheeks) directly opposite the lower 1st and 2nd molars. They may spread irregularly over the rest of the buccal mucosa. Rarely, they are found within the midportion of the lower lip, on the hard/soft palate, and even on the lacrimal caruncle (inner corner of the eye).
Timing: They nearly always precede the appearance of the typical skin rash by 2 to 3 days (specifically peaking 12-24 hours before the rash). They appear and disappear very rapidly, usually resolving within 12-18 hours. As they fade, a red, spotty discoloration of the mucosa may temporarily remain.

X. Stage 3: The Exanthem (The Rash)

Pattern of Spread (Cephalocaudal Progression)

The measles rash moves in a highly specific, downward directional flow (Head to Toe).

Day 1 (Onset): Usually starts as faint macules on the upper lateral parts of the neck, directly behind the ears, along the hairline, and on the posterior parts of the cheek.
First 24 Hours: The individual lesions become increasingly maculopapular (raised, bumpy, and red) as the rash spreads rapidly over the entire face, neck, upper arms, and upper part of the chest.
Succeeding 24 Hours (Day 2): The rash continues to spread strictly downward over the back, abdomen, entire arms, and thighs.
Days 2-3 of Rash: It finally reaches the feet. As it newly hits the feet, it simultaneously begins to fade on the face!

Characteristics & Severity

Confluence: The severity of the clinical disease is directly proportional to the extent and confluence (merging together) of the rash.
- Mild Measles: Rash tends to remain discrete (not confluent). Very few, if any, lesions on the lower legs.
- Severe Cases: Rash is highly confluent, merging into solid red sheets. The skin is completely covered, including the palms and soles. The face becomes distinctly swollen and disfigured.
Hemorrhagic Variations: The rash is often slightly hemorrhagic. In severe cases with a confluent rash, petechiae and extensive ecchymoses (bruising) may be present. "Black Measles" is a dreaded, severe hemorrhagic type of measles where frank bleeding occurs from the mouth, nose, or bowel, carrying a very high mortality rate.
Atypical Appearances: In mild cases, the rash may be less macular and more pinpoint, somewhat resembling scarlet fever or rubella. Infrequently, a faint macular or scarlatiniform rash may appear during the early prodromal stage, disappearing entirely before the typical measles rash arrives.

Resolution of the Illness

Absence of Rash: Complete absence of the rash is extremely rare. It primarily happens in patients who received immunoglobulin (Ig) during the incubation period, in some severe HIV-infected patients, or occasionally in infants <9 months old who still have partial maternal antibodies blunting the immune response.
Fading: The rash fades strictly downward in the exact same sequence in which it appeared (Face → Chest → Abdomen → Legs).
Desquamation (Peeling): As the rash fades, branny desquamation (fine, bran-like skin peeling) and a brownish discoloration occur, completely disappearing within 7-10 days. (Physiology note: The brownish color is due to hemosiderin deposition from the slight capillary hemorrhaging during the cytotoxic T-cell attack on the skin endothelial cells!).
Clinical Recovery: In uncomplicated cases, systemic symptoms rapidly subside within about 2 days as the rash hits the legs/feet, marked by an abrupt, dramatic drop in temperature to normal. Patients may appear desperately ill up to this point, but within 24 hours after the temperature drops, they miraculously appear well. Itching is generally very slight.

XI. Laboratory Diagnosis

Because the clinical picture is so classic (The 3 C's + Koplik spots + Cephalocaudal rash), the diagnosis is usually apparent clinically; laboratory confirmation is rarely needed in standard practice. However, it is rigorously utilized for epidemiological tracking, outbreak control, and atypical difficult cases.

Serology (IgM & IgG):
- Antibodies become detectable at the exact moment the rash appears.
- IgM Testing: Highly recommended. Measles-specific IgM indicates a current/recent acute infection. It is detectable for 1 month after illness.
  Warning: Sensitivity of IgM assays may be limited (producing false negatives) during the first 72 hours of the rash!
- IgG Titers: Testing of acute and convalescent sera (taken 2-4 weeks apart) that demonstrates a fourfold increase in IgG titer definitively confirms the diagnosis. Significant titers of measles antibodies in blood and CSF are crucially used to diagnose rare late complications like SSPE.
Molecular Detection (RT-PCR): Reverse transcriptase PCR is highly sensitive and specific. It is used to detect viral RNA in respiratory secretions, throat swabs, or blood. It is excellent for early detection before IgM rises.
Virus Isolation & Culturing: Isolation from clinical samples is useful to identify the specific genotype of the strain to track epidemiological transmission patterns globally. Grown in tissue culture using human embryonic cells, rhesus monkey kidney cells, or Vero/hSLAM cell lines.
Cytopathology & Secretion Smears: During the prodromal stage, smears of the nasal mucosa can be directly examined to demonstrate the presence of multinucleated Warthin-Finkeldey giant cells. Cytopathic Effect (CPE) in culture is visible in 5-10 days, characterized by the formation of multinucleated giant cells containing both intranuclear and intracytoplasmic inclusions. (Measles is unique in producing inclusions in both the nucleus AND the cytoplasm!).
General Laboratory Findings:
- White Blood Cell Count: Tends to be surprisingly low (Leukopenia) with a relative lymphocytosis.
- CSF findings (in Measles Encephalitis): Usually shows an increase in protein and a small increase in lymphocytes (pleocytosis). The glucose level remains strictly normal.

Public Health Rule: ALL suspected measles cases MUST be reported immediately to local or state health departments to mobilize outbreak response teams and initiate contact tracing!

Applied Clinical Question: Serology Interpretation

Scenario: A 6-year-old child presents with a fever, cough, and a confluent maculopapular rash that began on his face yesterday. The physician orders a Measles IgM test, which comes back negative. Should the physician rule out Measles based on this lab result?

Answer: No! As stated in the notes, the sensitivity of IgM assays is highly limited during the first 72 hours of the rash illness. Because the rash only began yesterday, this could easily be a false negative. The child must remain isolated, and the test should be repeated in a few days, or an RT-PCR should be utilized immediately.

XII. Differential Diagnosis

The maculopapular rash of rubeola (measles) must be carefully differentiated from a host of other viral, bacterial, and immune-mediated rashes:

Rubella (German Measles): Milder systemic symptoms, much shorter duration (3-day measles), prominent postauricular/suboccipital lymphadenopathy, and lacks Koplik spots.
Roseola Infantum (Exanthem Subitum): Caused by Human Herpesvirus 6 (HHV-6). Classic presentation is a high fever for 3-4 days that breaks abruptly, followed by the sudden appearance of a rash (whereas measles rash appears during the peak of the fever).
Infectious Mononucleosis (EBV): Can cause a maculopapular rash, especially if the patient is erroneously given ampicillin/amoxicillin. Features severe sore throat and massive splenomegaly.
Enteroviral Infections (Echovirus, Coxsackievirus) & Adenovirus: Can cause non-specific viral exanthems.
Bacterial Infections:
- Scarlet Fever (Group A Strep): Rash feels like rough sandpaper, spares the area around the mouth (circumoral pallor), and features a strawberry tongue.
- Meningococcemia: Petechial/purpuric rash that does not blanch on pressure. This is a rapidly fatal medical emergency!
- Rickettsial diseases (e.g., Rocky Mountain Spotted Fever): Rash classically starts on the wrists/ankles and moves inward.
Other: Toxoplasmosis, Kawasaki disease (features strawberry tongue, red cracked lips, and desquamation of hands/feet), Serum sickness, and allergic Drug rashes.

XIII. Treatment and Management

There is currently no specific antiviral therapy (like acyclovir for herpes) available for measles. Treatment is entirely supportive and aimed at preventing severe complications.

General Supportive Care

Antipyretics: Acetaminophen or Ibuprofen for fever control. (Aspirin is avoided in children due to the risk of Reye syndrome).
Hydration & Rest: Bed rest and maintenance of an adequate fluid intake (IV fluids if oral intake is poor) are strictly indicated.
Symptom Relief: Humidification may alleviate symptoms of laryngitis, croup, or an excessively irritating cough. It is best to keep the room comfortably warm rather than cool.
Photophobia Management: Patients with severe photophobia should be protected from exposure to strong light (keep the hospital room dim/drawn curtains).

Medical Interventions

Antibiotics: Strictly used ONLY for proven secondary bacterial complications like otitis media and bronchopneumonia. They require appropriate targeted antimicrobial therapy; they do not treat the viral measles infection itself and should not be used purely prophylactically.
Severe Complications: Encephalitis, Subacute Sclerosing Panencephalitis (SSPE), giant cell pneumonia, and Disseminated Intravascular Coagulation (DIC) must be assessed and managed individually. Good supportive care in a Pediatric Intensive Care Unit (PICU) is essential.
Ineffective Therapies: Immunoglobulin and corticosteroids are of highly limited value once the disease has fully manifested. Currently available antiviral compounds (like Ribavirin) are not definitively effective in standard practice.

Vitamin A Supplementation (Critical Intervention!)

The American Academy of Pediatrics and the WHO strongly recommend urgent Vitamin A supplementation for all children 6 months to 2 years of age hospitalized for measles/complications, and children >6 months with any immunodeficiency.

Physiological Expansion: Measles infection rapidly depletes the body's Vitamin A stores. Vitamin A is crucial for the rapid turnover, repair, and maintenance of epithelial cells (the lining of the gut and lungs) and retina function. Supplementation drastically reduces overall morbidity, prevents blindness (corneal ulceration/xerophthalmia), and significantly reduces mortality, especially in developing countries where baseline nutrition is poor.

Dosage Regimen (Single Oral Dose):

100,000 IU orally for children 6 months to 1 year of age.
200,000 IU for children 1 year of age or older.
Ophthalmologic involvement: If there is clinical evidence of severe Vitamin A deficiency (e.g., Bitot's spots, corneal clouding), additional identical doses should be given the next day and exactly 4 weeks later.

XIV. Potential Complications

Measles itself is brutal, but the chief complications of measles are what actually dictate the severe morbidity and mortality of the disease.

A. Respiratory Tract Complications

Commonest Cause of Death: Secondary bacterial pneumonia. The virus destroys the respiratory ciliated epithelium, creating a perfect breeding ground for bacteria.
Viral Pneumonia: Interstitial pneumonitis directly caused by the measles virus takes the form of Hecht giant cell pneumonia.
Bacterial Superinfection: Bronchopneumonia and Otitis Media (the most common overall complication) are frequent. Usually involves Pneumococcus, Group A Streptococcus, Staphylococcus aureus, and Haemophilus influenzae type b.
Airway Inflammation: Laryngitis, tracheitis, and bronchitis are common and may be due to the virus alone, causing a severe croup-like stridor.

High-Yield Immunology

T-Cell Anergy & Tuberculosis Reactivation

Measles exerts a profound, temporary immunosuppressive effect on the body, specifically blinding and destroying memory T-cells for weeks to months after infection. This leads to two massive clinical consequences:

Measles may radically exacerbate or reactivate a latent underlying Mycobacterium tuberculosis infection, leading to miliary TB.
There is a temporary loss of hypersensitivity reaction to tuberculin skin testing (PPD/Mantoux test). If you test a child for TB while they have measles (or shortly after), you will get a False Negative because their cellular immunity is temporarily paralyzed (a state called Anergy)!

B. Neurologic Complications

Neurologic issues are significantly more common in measles than in any of the other exanthematous (rash-causing) childhood diseases.

Encephalomyelitis: Incidence is 1-2 per 1,000 cases of measles (carrying a 10% mortality rate and high rates of permanent brain damage/deafness). There is absolutely no correlation between the severity of the rash and the likelihood of neurologic involvement, nor the initial encephalitic process and the ultimate prognosis.

Type of Encephalitis	Timing	Pathophysiology
Early Onset	Pre-eruptive or 2-5 days after rash appearance.	Caused by direct viral invasion, replication, and destruction of the brain tissue.
Late Onset	Occurs 1-2 weeks later.	Predominantly a post-infectious demyelinating disease. It reflects an immunologic cross-reaction (autoimmune molecular mimicry where the host's activated immune system attacks its own myelin).
Subacute Sclerosing Panencephalitis (SSPE)	Occurs years later (typically 1-15 years post-infection).	A rare, fatal, slow brain infection (Dawson's encephalitis). Occurs due to a defective, mutated measles virus that lacks the M-matrix protein required to bud out of the cell. Trapped, it slowly jumps from neuron to neuron via fusion. Marked by degeneration of cortex/white matter and profound inclusion bodies. Causes personality changes, myoclonic jerks, coma, and inevitable death.

Fatal Encephalitis: Has occurred aggressively in children receiving immunosuppressive treatment for leukemia or organ transplants.
Rare CNS Complications: Guillain-Barré syndrome, Hemiplegia, Cerebral thrombophlebitis, and Retrobulbar neuritis.

C. Cardiovascular & Other Complications

Myocarditis: Infrequent but serious. Transient electrocardiographic (ECG) changes may be relatively common during the febrile peak.
Noma (Cancrum Oris): A devastating, rapidly progressive polymicrobial gangrenous infection of the cheeks and mouth tissues. It is rare, seen mostly in severely malnourished children following measles immunosuppression.
Gangrene: Can appear elsewhere on extremities secondary to purpura fulminans or Disseminated Intravascular Coagulation (DIC) triggered by the severe inflammatory state.
Blindness: Due to severe corneal ulceration, aggressively exacerbated by concurrent Vitamin A deficiency.
Pregnancy: Measles infection in a pregnant woman results in fetal death or premature labor in up to 20% of cases. Importantly, unlike Rubella (which causes Congenital Rubella Syndrome), Measles does not typically cause specific birth defects (teratogenesis).

XV. Prognosis

United States / Developed Nations: Case fatality rates have decreased to exceptionally low levels for all age groups, largely due to improved socioeconomic conditions, baseline nutrition, and highly effective antibacterial therapy for secondary infections. However, despite the decline, the baseline fatality rate is still 1-3 deaths per 1,000 reported cases. Deaths are primarily due to respiratory pneumonia or bacterial superinfections.
Developing Countries: Frequently occurs in very young infants. Because of concomitant severe malnutrition, crowding, and prevalent Vitamin A deficiency, the disease is far more severe and carries a terrifyingly high mortality rate (sometimes exceeding 10% in refugee camp settings).
Susceptible Populations: Historically, when measles is introduced into a highly susceptible, previously unexposed isolated population (e.g., indigenous island populations), the results are disastrous, wiping out significant percentages of the population.

XVI. Prevention and Vaccination

Isolation Precautions

Especially in hospitals, clinics, or institutional settings, strict airborne isolation (negative pressure rooms, N95 masks for staff) must be maintained from the 7th day after exposure until 5 days after the rash has appeared.

Active Immunization (The Vaccine)

The primary and most powerful tool for control. It is a Live Attenuated Vaccine, almost universally delivered as the MMR (Measles, Mumps, Rubella) or MMRV (plus Varicella) combined vaccine.

Schedule (US/Developed Nations): Initial immunization is recommended at 12-15 months of age (delayed to prevent interference from maternal IgG antibodies). A second dose is recommended routinely at 4-6 years of age (prior to school entry) to catch the 5% of children who fail to develop immunity from the first dose. Adolescents entering college or the workforce who have not received the second dose should be immediately immunized.
Schedule (Global/Developing Nations - WHO guidelines): First dose (MR1) is given earlier at 9 months old due to the extremely high risk of infant mortality in these regions overriding the risk of maternal antibody interference. Second dose (MR2) is given at 18 months old.

Vaccine Contraindications (DO NOT GIVE TO)

Because the MMR is a Live vaccine (the virus can still replicate, albeit weakly), it is absolutely contraindicated in:

Pregnant women (theoretical risk of infecting the fetus).
Children with primary immunodeficiency (e.g., severe combined immunodeficiency).
Patients with active, untreated tuberculosis, active cancer, or recent organ transplantation.
Those receiving long-term heavy immunosuppressive therapy (e.g., high-dose steroids, chemotherapy).
Severely immunocompromised HIV-infected children.

Exception for HIV: HIV-infected children who do NOT have severe immunosuppression (e.g., CD4 counts >15%) and lack evidence of measles immunity may and should receive the measles vaccine, as wild-type measles would be far more deadly to them!

XVII. Post-Exposure Prophylaxis (PEP)

If a highly susceptible person is inadvertently exposed to measles, we can prevent or attenuate the disease using two specific methods, strictly depending on elapsed time and patient health status.

1. Passive Immunization

Immune Globulin (Ig)

Must be given within 6 days (144 hours) of exposure.

Indications & Dosing: Susceptible household/hospital contacts who are younger than 12 months or pregnant should receive Ig at a dose of 0.25 mL/kg (maximum 15 mL) intramuscularly.
Immunocompromised: Immunocompromised persons should receive a much higher dose of 0.5 mL/kg (maximum 15 mL) IM, absolutely regardless of their prior immunization status.
Infants under 6 months: If born to a completely nonimmune mother, they must receive Ig. If born to a verified immune mother, they are considered naturally protected by lingering maternal antibodies and do not need it.

2. Active Immunization

Vaccine as PEP

Must be given within 72 hours (3 days) of exposure to outpace the wild-type virus.

Susceptible children 6-12 months of age should be actively vaccinated as an emergency measure. However, this early emergency dose does not count towards their required routine childhood series; they must be revaccinated at 12-15 months.
Susceptible children 12 months or older should receive the vaccine alone if within the 72 hr window.
Golden Rule: Pregnant women and immunocompromised persons must receive Immune Globulin, NEVER the live vaccine.

Applied Clinical Question: Post-Exposure Prophylaxis

Scenario: A 7-month-old infant is exposed to a confirmed case of measles at a daycare center. The mother brings the infant to your clinic 4 days (96 hours) after the exposure occurred. What is the appropriate Post-Exposure Prophylaxis for this infant?

Answer: The infant must receive Immune Globulin (Ig). A live vaccine must be given within 72 hours (3 days) to work effectively as PEP, and we are at 96 hours. Furthermore, this infant is too young (under 12 months) for standard routine vaccination anyway. Therefore, they must receive passive immunization with Immune Globulin, which remains highly effective if given within 6 days of exposure!

XVIII. References & Source Literature

Centers for Disease Control and Prevention (CDC): Epidemiology of measles – United States, 2001–2003. Morbidity and Mortality Weekly Report (MMWR), 2004.
Centers for Disease Control and Prevention (CDC): Progress towards measles elimination, western hemisphere, 2002–2003.
Yeung LF, et al.: A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics, 2005.
Bellini WJ, et al.: Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. Journal of Infectious Diseases, 2005.